Alimentary pharmacology & therapeutics
-
Aliment. Pharmacol. Ther. · Dec 2020
Randomized Controlled TrialUstekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.
The ongoing UNIFI long-term extension evaluates subcutaneous ustekinumab for moderate-to-severe ulcerative colitis (UC) from weeks 44 through 220. ⋯ The efficacy of ustekinumab in patients with UC was sustained through 92 weeks. No new safety signals were observed (ClinicalTrials.gov number, NCT02407236).
-
Aliment. Pharmacol. Ther. · Oct 2020
Multicenter Study Comparative StudyComparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease.
Anti-tumour necrosis factor (TNF) agents are effective in Crohn's disease but some patients lose response and require alternative biologic therapy. There are few data on comparative effectiveness of vedolizumab and ustekinumab in this setting. ⋯ Ustekinumab appeared more effective in treating anti-TNF-refractory Crohn's disease and more patients persisted with therapy.